Abstract
To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1731-1736 |
| Number of pages | 6 |
| Journal | Archives of Ophthalmology |
| Volume | 109 |
| Issue number | 12 |
| State | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat. / Benner, J. D.; Morse, Lawrence S; Toth, C. A.; Landers, M. B.; Hjelmeland, Leonard M.
In: Archives of Ophthalmology, Vol. 109, No. 12, 1991, p. 1731-1736.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat
AU - Benner, J. D.
AU - Morse, Lawrence S
AU - Toth, C. A.
AU - Landers, M. B.
AU - Hjelmeland, Leonard M
PY - 1991
Y1 - 1991
N2 - To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.
AB - To explore the feasibility of using human recombinant tissue-type plasminogen activator in the management of subretinal hemorrhage, we examined the toxic effects of a commercial preparation of human recombinant tissue- type plasminogen activator in the subretinal space of the holangiotic retina of the cat. Various concentrations of human recombinant tissue-type plasminogen activator and controls were infused into the subretinal space with a glass micropipette (40- to 60-μm tip) to form a retinal bleb. Concentrations from 2.5 mg/L to 200 mg/L were well tolerated without ultrastructural toxic effects, while 1000 mg/L of human recombinant tissue- type plasminogen activator caused severe, irreversible toxic effects to the photoreceptor-retinal pigment epithelium complex. This toxic effect appeared to be due to the carrier vehicle rather than the human recombinant tissue- type plasminogen activator protein itself. Our results demonstrate that commercially prepared human recombinant tissue-type plasminogen activator can be safely used in the subretinal space of the cat with the range necessary for fibrinolysis.
UR - http://www.scopus.com/inward/record.url?scp=0026409936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026409936&partnerID=8YFLogxK
M3 - Article
C2 - 1841586
AN - SCOPUS:0026409936
VL - 109
SP - 1731
EP - 1736
JO - JAMA Ophthalmology
JF - JAMA Ophthalmology
SN - 2168-6165
IS - 12
ER -